Even with the emergence of effective vaccine candidates, the percentage of COVID-related ESG content hasn’t broken out of the range of ~25% of total volume.
The COVID-19 Response Signal spiked from 6% to 10.8% over the past two weeks, a level not seen since May, with the news of likely viable vaccines from Pfizer, BioNTech, and Moderna.
The SASB category of Access & Affordability, fueled by vaccine news, rocketed to 24% of the share of total COVID-19 news in the past two weeks. It was the highest level of any individual SASB category since early June, when Employee Health and Safety reached that level as workplaces grappled with issues related to social distancing and adequate PPE.
Social data leads the dimensions with 40% of data, while Environment data remains at 36% of ESG data, maintaining a recent level as climate-related policy and severe weather events capture attention.
Both the US and Europe have steep curves of new case growth, with Europe's showing a dip that may show a slowing infection rate. Neither has seen a similar pronounced uptick in COVID-19 related conversation. Rarely mentioned in this report in the past six months is China, which continues reporting astonishingly low new case rates in the 100-200 range each week.
Unsurprisingly, Biotechnology & Pharmaceuticals showed a massive ratio of COVID-related content to non-COVID content, reaching a level of 350%.
COVID-19 volume for vaccine makers broke through the ceiling in the past two weeks. In aggregate, the Response signal sentiment for the top 10 firms in the Healthcare Sector rose 55% from our last installment two weeks prior.
Continuing with a focus on racial equality, we again highlight key recent Spotlight Events. This week, racial justice-related data shows banks stepping up on diversity and racial justice, with HSBC vowing to double its senior Black staff, and TCF Bank promising $1 billion in loans to minority and women-owned small businesses.